

# AIN HOLDINGS INC.

March 1, 2024

### 1. Consolidated Results

| (¥ million)                             | FY4/23 3Q<br>results | FY4/24 3Q<br>results | YoY<br>change | YoY<br>change(%) |
|---|----------------------|----------------------|---------------|------------------|
| Net sales                               | 263,906              | 296,360              | +32,454       | +12.3            |
| Gross profit                            | 39,692               | 43,213               | +3,521        | +8.9             |
| % of net sales                          | 15.0                 | 14.6                 |               |                  |
| SG&A expenses                           | 28,006               | 28,907               | +901          | +3.2             |
| % of net sales                          | 10.6                 | 9.8                  |               |                  |
| Operating profit                        | 11,685               | 14,305               | +2,620        | +22.4            |
| % of net sales                          | 4.4                  | 4.8                  |               |                  |
| Ordinary profit                         | 12,367               | 15,050               | +2,683        | +21.7            |
| % of net sales                          | 4.7                  | 5.1                  |               |                  |
| Profit attributable to owners of parent | 6,628                | 8,730                | +2,102        | +31.7            |
| % of net sales                          | 2.5                  | 2.9                  |               |                  |
| Earnings per<br>share(¥)                | 188.70               | 248.51               | +59.81        | +31.7            |

■ Year-on-Year

Figures in the table are rounded down

| ■Vs Plan<br>(¥ million)                 | FY4/24 3Q<br>plan | FY4/24 3Q<br>results | Vs plan<br>change | Vs plan<br>change(%) |
|---|-------------------|----------------------|-------------------|----------------------|
| Net sales                               | 292,551           | 296,360              | +3,809            | +1.3                 |
| Gross profit                            | 42,721            | 43,213               | +492              | +1.2                 |
| % of net sales                          | 14.6              | 14.6                 |                   |                      |
| SG&A expenses                           | 29,453            | 28,907               | (546)             | (1.9)                |
| % of net sales                          | 10.1              | 9.8                  |                   |                      |
| Operating profit                        | 13,268            | 14,305               | +1,037            | +7.8                 |
| % of net sales                          | 4.5               | 4.8                  |                   |                      |
| Ordinary profit                         | 14,038            | 15,050               | +1,012            | +7.2                 |
| % of net sales                          | 4.8               | 5.1                  |                   |                      |
| Profit attributable to owners of parent | 7,609             | 8,730                | +1,121            | +14.7                |
| % of net sales                          | 2.6               | 2.9                  |                   |                      |
| Earnings per<br>share(¥)                | 216.60            | 248.51               | +31.91            | +14.7                |

Figures in the table are rounded down

#### 2. Segment Information (Dispensing Pharmacy Business)

| (¥ million)      | FY4/23 3Q<br>results | FY4/24 3Q<br>results | YoY<br>change | YoY<br>change(%) |
|------------------|----------------------|----------------------|---------------|------------------|
| Net sales        | 236,396              | 265,019              | +28,623       | +12.1            |
| Gross profit     | 29,448               | 31,508               | +2,060        | +7.0             |
| % of net sales   | 12.5                 | 11.9                 |               |                  |
| SG&A expenses    | 12,067               | 12,551               | +484          | +4.0             |
| % of net sales   | 5.1                  | 4.7                  |               |                  |
| Operating profit | 17,380               | 18,957               | +1,577        | +9.1             |
| % of net sales   | 7.4                  | 7.2                  |               |                  |
| Segment profit   | 18,023               | 19,713               | +1,690        | +9.4             |
| % of net sales   | 7.6                  | 7.4                  |               |                  |

#### ■ Year-on-Year

Figures in the table are rounded down

Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

#### ∎Vs Plan

| (¥ million)      | FY4/24 3Q<br>plan | FY4/24 3Q<br>results | Vs plan<br>change | Vs plan<br>change(%) |
|------------------|-------------------|----------------------|-------------------|----------------------|
| Net sales        | 261,480           | 265,019              | +3,539            | +1.4                 |
| Gross profit     | 31,088            | 31,508               | +420              | +1.4                 |
| % of net sales   | 11.9              | 11.9                 |                   |                      |
| SG&A expenses    | 12,598            | 12,551               | (47)              | (0.4)                |
| % of net sales   | 4.8               | 4.7                  |                   |                      |
| Operating profit | 18,490            | 18,957               | +467              | +2.5                 |
| % of net sales   | 7.1               | 7.2                  |                   |                      |
| Segment profit   | 19,214            | 19,713               | +499              | +2.6                 |
| % of net sales   | 7.3               | 7.4                  |                   |                      |

Figures in the table are rounded down

Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

#### 3. Segment Information (Cosmetic and Drug Store Business)

| (¥ million)      | FY4/23 3Q<br>results | FY4/24 3Q<br>results | YoY<br>change | YoY<br>change(%) |
|------------------|----------------------|----------------------|---------------|------------------|
| Net sales        | 18,836               | 22,905               | +4,069        | +21.6            |
| Gross profit     | 7,102                | 8,800                | +1,698        | +23.9            |
| % of net sales   | 37.7                 | 38.4                 |               |                  |
| SG&A expenses    | 6,401                | 6,588                | +187          | +2.9             |
| % of net sales   | 34.0                 | 28.8                 |               |                  |
| Operating profit | 700                  | 2,212                | +1,512        | +216.0           |
| % of net sales   | 3.7                  | 9.7                  |               |                  |
| Segment profit   | 737                  | 2,246                | +1,509        | +204.7           |
| % of net sales   | 3.9                  | 9.8                  |               |                  |

#### ■ Year-on-Year

Figures in the table are rounded down

Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

#### ∎Vs Plan

| (¥ million)      | FY4/24 3Q<br>plan | FY4/24 3Q<br>results | Vs plan<br>change | Vs plan<br>change(%) |
|------------------|-------------------|----------------------|-------------------|----------------------|
| Net sales        | 22,420            | 22,905               | +485              | +2.2                 |
| Gross profit     | 8,540             | 8,800                | +260              | +3.0                 |
| % of net sales   | 38.1              | 38.4                 |                   |                      |
| SG&A expenses    | 6,590             | 6,588                | (2)               | 0.0                  |
| % of net sales   | 29.4              | 28.8                 |                   |                      |
| Operating profit | 1,950             | 2,212                | +262              | +13.4                |
| % of net sales   | 8.7               | 9.7                  |                   |                      |
| Segment profit   | 1,958             | 2,246                | +288              | +14.7                |
| % of net sales   | 8.7               | 9.8                  |                   |                      |

Figures in the table are rounded down

Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income

#### 4. Sales Verification

#### Average Average Prescription Prescription Net sales Net sales prescription prescription (%) volume (%) volume price price +6.3+1.7Same store (1,064) +7.5+1.2Same store (1,064) +1.0+0.7Store openings in the Store openings in the +57.1+6.6+2.8+66.3+1.4+1.6previous year (133) previous year (133) +0.7Total (1,221) +12.3+10.2+2.0Total (1,221) +1.4+0.7

#### Dispensing Pharmacy Business (YoY)

#### Cosmetic and Drug Store Business (YoY)

#### Cosmetic and Drug Store Business (Vs Plan)

| (%)                                     | Net sales | Number of customers | Average<br>spending per<br>customer | (%)                                     | Net sales | Number of customers | Average<br>spending per<br>customer |
|---|-----------|---------------------|-------------------------------------|---|-----------|---------------------|-------------------------------------|
| Same store (68)                         | +22.5     | +12.5               | +8.9                                | Same store (68)                         | +0.4      | (4.2)               | +4.8                                |
| Store openings in the previous year (8) | +156.8    | +152.8              | +1.6                                | Store openings in the previous year (8) | +9.8      | +5.3                | +4.3                                |
| Total (81)                              | +21.6     | +12.9               | +7.7                                | Total (81)                              | +2.2      | (3.6)               | +6.0                                |

### ■ Dispensing Pharmacy Business (Vs Plan)

#### 5. Consolidated Balance Sheet

#### Assets

| (¥ million)                           | End-FY4/23 3Q | End-FY4/23 | End-FY4/24 3Q | Change  |
|---------------------------------------|---------------|------------|---------------|---------|
| Cash on hand and in banks             | 46,193        | 46,796     | 50,057        | +3,261  |
| Accounts receivable                   | 11,269        | 13,249     | 14,007        | +758    |
| Inventories                           | 23,629        | 21,586     | 27,093        | +5,507  |
| Total current assets                  | 95,490        | 98,305     | 106,837       | +8,532  |
| Buildings and structures, net         | 20,591        | 21,407     | 27,010        | +5,603  |
| Land                                  | 10,584        | 10,602     | 10,116        | (486)   |
| Total property, plant and equipment   | 38,519        | 39,459     | 42,745        | +3,286  |
| Goodwill                              | 47,539        | 46,443     | 43,947        | (2,496) |
| Total intangible fixed assets         | 53,110        | 52,343     | 50,664        | (1,679) |
| Investments in securities             | 2,938         | 2,720      | 3,427         | +707    |
| Deferred tax assets                   | 6,118         | 5,990      | 6,287         | +297    |
| Deposits and guarantees               | 24,823        | 24,507     | 24,713        | +206    |
| Total investments and other<br>assets | 42,443        | 41,641     | 43,440        | +1,799  |
| Total fixed assets                    | 134,072       | 133,444    | 136,850       | +3,406  |
| Total assets                          | 229,562       | 231,750    | 243,688       | +11,938 |

Figures in the table are rounded down

Change: End-FY4/24 3Q compared with end-FY4/23

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥10,447million

#### Liabilities and Net Assets

| (¥ million)                      | End-FY4/23 3Q | End-FY4/23 | End-FY4/24 3Q | Change  |
|----------------------------------|---------------|------------|---------------|---------|
| Accounts payable                 | 60,972        | 58,698     | 67,987        | +9,289  |
| Short-term debt                  | 4,036         | 3,670      | 3,183         | (487)   |
| Total current liabilities        | 92,823        | 92,986     | 100,847       | +7,861  |
| Long-term debt                   | 5,816         | 5,021      | 2,366         | (2,655) |
| Total long-term liabilities      | 12,995        | 12,218     | 9,561         | (2,657) |
| Total liabilities                | 105,819       | 105,204    | 110,409       | +5,205  |
| Common stock                     | 21,894        | 21,894     | 21,894        | -       |
| Capital surplus                  | 20,504        | 20,504     | 20,499        | (5)     |
| Retained earnings                | 83,357        | 85,963     | 92,586        | +6,623  |
| Total shareholders' equity       | 123,756       | 126,362    | 132,997       | +6,635  |
| Total net assets                 | 123,743       | 126,546    | 133,278       | +6,732  |
| Total liabilities and net assets | 229,562       | 231,750    | 243,688       | +11,938 |

Figures in the table are rounded down

Change: End-FY4/24 3Q compared with end-FY4/23

## 6. FY4/24 Plan (Consolidated)

| (¥ million)                             | FY4/23<br>results | FY4/24<br>initial plan | FY4/24<br>revised plan | YoY<br>change<br>(%) | Vs initial<br>plan change<br>(%) |
|---|-------------------|------------------------|------------------------|----------------------|----------------------------------|
| Net sales                               | 358,742           | 375,000                | 390,263                | +8.8                 | +4.1                             |
| Gross profit                            | 53,698            | 55,413                 | 58,106                 | +8.2                 | +4.9                             |
| % of net sales                          | 15.0              | 14.8                   | 14.9                   |                      |                                  |
| SG&A expenses                           | 37,694            | 39,750                 | 39,656                 | +5.2                 | (0.2)                            |
| % of net sales                          | 10.5              | 10.6                   | 10.2                   |                      |                                  |
| Operating profit                        | 16,004            | 15,663                 | 18,450                 | +15.3                | +17.8                            |
| % of net sales                          | 4.5               | 4.2                    | 4.7                    |                      |                                  |
| Ordinary profit                         | 17,064            | 16,302                 | 19,340                 | +13.3                | +18.6                            |
| % of net sales                          | 4.8               | 4.3                    | 5.0                    |                      |                                  |
| Profit attributable to owners of parent | 9,234             | 8,250                  | 10,000                 | +8.3                 | +21.2                            |
| % of net sales                          | 2.6               | 2.2                    | 2.6                    |                      |                                  |
| Earnings per<br>share(¥)                | 262.87            | 234.84                 | 284.64                 | +8.3                 | +21.2                            |
| Annual dividend (¥)                     | 60.00             | 60.00                  | 60.00                  | 0.0                  | 0.0                              |

Figures in the table are rounded down

#### 7. Transition of Store Openings

|         | FY4/16 | FY4/17 | FY4/18 | FY4/19 | FY4/20 | FY4/21 | FY4/22 | FY4/23 | FY4/24<br>3Q |
|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------------|
| Organic | 32     | 27     | 25     | 23     | 14     | 15     | 25     | 27     | 14           |
| M&A     | 110    | 182    | 11     | 134    | 6      | 14     | 24     | 114    | 11           |
| Total   | 881    | 1,066  | 1,029  | 1,132  | 1,088  | 1,065  | 1,099  | 1,209  | 1,221        |

#### ■ Number of Store Openings in Dispensing Pharmacy Business

#### Number of Store Openings in Cosmetic and Drug Store Business

|         | FY4/16 F | Y4/17 F | Y4/18 F | Y4/19 F | Y4/20 F | Y4/21 F | Y4/22 F | Y4/23 | FY4/24<br>3Q |
|---------|----------|---------|---------|---------|---------|---------|---------|-------|--------------|
| Organic | 5        | 9       | 4       | 7       | 15      | 11      | 12      | 8     | 5            |
| Total   | 52       | 52      | 48      | 54      | 63      | 69      | 78      | 78    | 81           |

Inquiries related to this presentation should be addressed to

#### AIN HOLDINGS INC. Corporate Planning Division TEL(81)11-814-0010 FAX(81)11-814-5550 https://www.ainj.co.jp/corporate/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

